Pen-to-Vial Tirzepatide Dose Conversion: The Math and the Tracker
5 min read
CTO & Co-Founder of miora. Stanford Biodesign, ex-Tesla.
Switching from a branded tirzepatide pen to a compounded vial is increasingly common in 2026 for cost reasons. The compound is the same; the dispensing format and the dose math change completely. This is the conversion reference plus the operational tracking protocol.
Pen-to-vial conversion is straightforward math but the failure mode is consistent: wrong concentration assumption produces a dose error. Log the vial info once and have the tracker confirm units per dose every time.
Common compounded tirzepatide concentrations are 10 mg/mL and 20 mg/mL. Verify the concentration on the vial label before computing the dose.
U-100 insulin syringes are the standard. A '40 unit' dose at 10 mg/mL is 0.4 mL or 4 mg of tirzepatide. Confirm syringe scale.
The most common reason for switching tirzepatide from pen to vial in 2026 is cost. Branded Mounjaro and Zepbound prices vary by insurance and discount programs but commonly run $1000+ per month at the higher doses. Compounded tirzepatide can run 60-80% less. The compound is the same molecule, dispensed differently. The dose math is the new burden, and getting it wrong is the most common error users make in the first weeks after switching. This guide is the conversion reference plus the operational tracker setup.
Three factors drive the pen-to-vial switch in 2026:
Cost. Branded tirzepatide is expensive. Compounded tirzepatide, when sourced from a reputable 503A pharmacy, can run a fraction of the branded price. For users paying out of pocket or with high-deductible insurance, the difference is meaningful.
Insurance coverage changes. Plans drop tirzepatide from formularies; prior authorization requirements increase; copay structures shift. Users who had branded coverage often lose it mid-protocol.
Supply availability. Periodic shortages of specific dose steps on branded tirzepatide push users to compound sources for continuity.
The compound delivered is the same active molecule when the compounding pharmacy is competent. The user-side change is the dispensing format and the dose math. This is the operational guide for the switch itself.
The formula for computing units on a U-100 insulin syringe:
units = (target dose mg / concentration mg/mL) × 100
Equivalently: units = target dose mg × (100 / concentration mg/mL)
Worked examples:
Vial at 10 mg/mL, target dose 5 mg. units = (5 / 10) × 100 = 50 units. Volume = 0.5 mL.
Vial at 10 mg/mL, target dose 7.5 mg. units = (7.5 / 10) × 100 = 75 units. Volume = 0.75 mL.
Vial at 20 mg/mL, target dose 10 mg. units = (10 / 20) × 100 = 50 units. Volume = 0.5 mL.
Vial at 20 mg/mL, target dose 12.5 mg. units = (12.5 / 20) × 100 = 62.5 units. Round to 63 units. Volume = 0.625 mL.
The math is straightforward but it is done at 7 a.m. and the consistent error is using the wrong concentration. A vial dispensed at 20 mg/mL but drawn as if it were 10 mg/mL produces double the intended dose - a substantial overdose. Verify the concentration on the vial every time, or log it once at reconstitution and have miora confirm units per dose at every injection.
Common target doses at common compounded concentrations, in units on a U-100 insulin syringe:
The table below covers the standard pen dose steps (2.5 to 15 mg) at the two most common compounded concentrations (10 mg/mL and 20 mg/mL). Always verify the concentration on the actual vial; some pharmacies use other concentrations.
Four error patterns account for the majority of pen-to-vial dosing mistakes.
Wrong concentration assumed. The vial label is the only source of truth. Do not assume the new vial is the same concentration as the last one if it came from a different pharmacy or batch. miora prompts for concentration confirmation at each new vial.
Wrong syringe scale. U-100 insulin syringes have 100 units per mL. U-40 and tuberculin syringes have different scales. Use U-100 unless your prescriber has specified otherwise. Mixing syringe types within a protocol is a common source of error.
Wrong dose step assumed. Users transitioning from pen to vial sometimes mis-remember which titration step they were on. The pen labels are the source of truth for the prior step.
Rounding errors. Doses like 12.5 mg at 20 mg/mL produce non-integer units (62.5). Round to the nearest unit; consistent rounding direction matters less than consistency.
miora's dose calculator handles all four. Log the vial info, log the target dose, and the calculator confirms units. If the result looks unusual relative to recent doses, miora flags it.
Compounded tirzepatide is usually dispensed pre-reconstituted (ready to draw and inject), unlike compound semaglutide which is often dispensed lyophilized for user reconstitution. Common formats:
Pre-reconstituted multi-dose vial. Typical: 30 mg vial in 3 mL of bacteriostatic water. 10 mg/mL concentration. Used over multiple weeks.
Lyophilized vial for user reconstitution. Less common but available. User reconstitutes with bac water dispensed alongside.
Stability of reconstituted compound tirzepatide is generally 28-56 days refrigerated, depending on bacteriostatic water source. Inventory math:
30 mg vial at 10 mg/mL, weekly dosing at 7.5 mg. 30 / 7.5 = 4 doses. 4 weeks of supply. Within stability window.
30 mg vial at 10 mg/mL, weekly at 10 mg. 3 doses. 3 weeks of supply.
30 mg vial at 10 mg/mL, weekly at 5 mg. 6 doses. 6 weeks of supply - exceeds 28-day window; either reconstitute partial volume or plan for some product loss.
miora tracks the vial inventory and the stability window. Each injection decrements the available volume; if a vial is approaching stability limit with product remaining, miora flags it in the morning summary.
The first 4 weeks after switching from pen to vial are the calibration period. The compound is the same so the side-effect profile should be similar; the user-side variables (technique, dose precision, vial source variability) introduce differences.
Tracking priorities in the first 4 weeks:
Daily side-effect rubric. Compare to the prior pen weeks. Material difference may indicate a dose calculation error or source quality issue.
Injection-site reactions. Vial-and-syringe technique varies more than pen technique. Persistent site reactions warrant technique review.
Smoothed weight trend. Should continue on the same trajectory as before the switch. If trend changes significantly, dose math or source quality may be involved.
Dose log accuracy. Cross-check every injection in week 1 to ensure the conversion math is consistent.
By week 4, the dose-math errors have either surfaced (and been corrected) or stabilized into the new routine. Continuing logging discipline is the protection.
The miora workflow for pen-to-vial users adds the dose calculator to the standard tirzepatide tracking.
At first vial: One text: 'new vial: tirzepatide 30 mg at 10 mg/mL, [pharmacy], reconstitution date today.' miora logs the vial, calculates expected doses available, and notes the stability window.
At each injection: 'injected tirz, target dose 7.5 mg, 75 units on U-100, right thigh.' miora confirms the math (75 units at 10 mg/mL = 7.5 mg), decrements the inventory, and notes the next planned injection.
Daily check: Standard tirzepatide rubric - nausea, fatigue, GI, hydration, protein, mood. miora maps to day post-injection automatically.
Weekly summary: Side-effect curve, smoothed weight, protein and hydration trends, inventory remaining and stability status.
The morning math goes away. The dose precision question is structurally answered by the calculator. The user focuses on hitting protein and hydration, not on remembering whether the concentration was 10 or 20 mg/mL.
Three boundaries.
This guide does not recommend switching from pen to vial. The decision belongs with your prescriber and depends on cost, coverage, and clinical context. Some users will find the branded pen worth the cost difference; some will not.
This guide does not recommend specific compounding pharmacies. Source quality varies; choose based on your prescriber's recommendation or appropriate due diligence.
This guide does not source tirzepatide in any format. miora does not source any compound. This content is for informational purposes only and is not medical advice. Tirzepatide requires prescription and clinician supervision regardless of dispensing format.
111
